Log in

NYSE:NVRO - Nevro Stock Price, Forecast & News

$89.45
-10.53 (-10.53 %)
(As of 04/2/2020 03:18 AM ET)
Today's Range
$87.32
Now: $89.45
$96.46
50-Day Range
$70.23
MA: $116.35
$144.31
52-Week Range
$54.00
Now: $89.45
$148.05
Volume575,200 shs
Average Volume530,849 shs
Market Capitalization$2.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.55
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Read More
Nevro logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone650-251-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$390.26 million
Book Value$6.98 per share

Profitability

Net Income$-103,690,000.00

Miscellaneous

Employees804
Market Cap$2.85 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.


Nevro (NYSE:NVRO) Frequently Asked Questions

How has Nevro's stock been impacted by COVID-19 (Coronavirus)?

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has decreased by 18.5% and is now trading at $89.45. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Nevro?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nevro.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Nevro.

How were Nevro's earnings last quarter?

Nevro Corp (NYSE:NVRO) posted its quarterly earnings data on Tuesday, February, 25th. The medical equipment provider reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.18. The medical equipment provider had revenue of $114.37 million for the quarter, compared to analysts' expectations of $110.83 million. Nevro had a negative net margin of 26.57% and a negative return on equity of 49.96%. View Nevro's earnings history.

What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $86.4-86.9 million, compared to the consensus revenue estimate of $96.96 million.

What price target have analysts set for NVRO?

12 Wall Street analysts have issued 12 month price targets for Nevro's stock. Their forecasts range from $65.00 to $158.00. On average, they expect Nevro's stock price to reach $121.50 in the next twelve months. This suggests a possible upside of 35.8% from the stock's current price. View analysts' price targets for Nevro.

Has Nevro been receiving favorable news coverage?

Media stories about NVRO stock have trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nevro earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutNevro.

Are investors shorting Nevro?

Nevro saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,539,800 shares, an increase of 10.9% from the February 27th total of 2,290,000 shares. Based on an average daily trading volume, of 397,600 shares, the short-interest ratio is currently 6.4 days. Approximately 8.4% of the shares of the company are sold short. View Nevro's Current Options Chain.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Micron Technology (MU), Adobe (ADBE), Incyte (INCY), Ionis Pharmaceuticals (IONS), Starbucks (SBUX) and ABIOMED (ABMD).

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
  • Mr. Patrick Schmitz, VP of Operations (Age 59)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)
  • Mr. Doug Alleavitch, VP of Quality (Age 58)
  • Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $89.45.

How big of a company is Nevro?

Nevro has a market capitalization of $2.85 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe. View additional information about Nevro.

What is Nevro's official website?

The official website for Nevro is http://www.nevro.com/.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]


MarketBeat Community Rating for Nevro (NYSE NVRO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  438 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  748
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Featured Article: Death Cross

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel